CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aratana Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aratana Therapeutics Inc
11400 Tomahawk Creek Pkwy Ste
Phone: (913) 353-1000p:913 353-1000 Leawood, KS  66211-2730  United States Fax: (913) 904-9641f:913 904-9641
This company ceased filing statements with the SEC on 7/29/2019.
This company is no longer actively traded on any major stock exchange.
Business Summary
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201912/31/2018YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairperson of the Board Wendy L.Yarno 65 8/10/2015 10/18/2013
President, Chief Executive Officer, Director Craig A.Tooman 54 1/17/2019 4/1/2012
Chief Financial Officer, Treasurer Rhonda L.Hellums 2/1/2019 2/1/2019
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Vet Therapeutics, Inc 2683 Via De La Valle Del Mar CA United States

Business Names
Business Name
Aratana Therapeutics NV
PETX
Vet Therapeutics, Inc.

General Information
Number of Employees: 79 (As of 3/8/2019)
Outstanding Shares: 49,002,724 (As of 6/13/2019)
Shareholders: 71
Stock Exchange: NASD
Federal Tax Id: 383826477
Fax Number: (913) 904-9641


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023